|
LipidManagement™ is certified
for CME credit. Save your quarterly issues this year, as they
will be needed for the CME posttest in December 2002.
LEARNING OBJECTIVES
After reading the articles in this issue of LipidManagement™,
participants should be able to:
| • |
Discuss the relevance and benefits of
CHD risk management in the older patient |
| • |
Utilize a more aggressive approach to
lipid-lowering in older patients to reduce their risk
of coronary heart disease |
| • |
Explain the process of LDL
apheresis and how it affects cardiovascular disease by
decreasing LDL-C and certain inflammatory markers |
Intended audience:
primary care physicians, cardiologists, endocrinologists
Release date: June 15, 2002
End date: December 31, 2003
This CME activity is sponsored by Thomson Professional Postgraduate
Services®, Secaucus, NJ.
Thomson Professional Postgraduate Services®
is accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
Thomson Professional Postgraduate Services®
designates this educational activity for a maximum of 2 hours
in category 1 credit toward the AMA Physician's Recognition
Award. Each physician should claim only those hours of credit
that he/she actually spent in the activity.
|
|
|
PROSPER Focuses on Persons Older Than Age 70
Although growing evidence suggests that statin therapy may reduce
the risk for vascular disease in persons older than 70 years of age,
no large-scale trial has examined this issue until now. The Prospective
Study of Pravastatin in the Elderly at Risk is a randomized double-blind
placebo-controlled evaluation of the effect of pravastatin on the
combined end point of CHD death, nonfatal MI, and stroke. A total
of 5,804 men and women aged 70 to 82 years with baseline cholesterol
levels of 155–350 mg/dL and good cognitive function have been
enrolled. About 50% of the subjects have preexisting vascular disease,
and 50% are at high risk for developing this condition because of
hypertension, cigarette smoking, or type 2 diabetes. They will be
followed for 3 to 5 years.
Reference
| Shepherd J, Blauw GJ, Murphy MB,
et al, for the PROSPER Study Group. The design of a prospective
study of pravastatin in the elderly at risk (PROSPER). Am
J Cardiol. 1999;84:1192-1197. |
|